The Silent Threat — Managing Fatty Liver Disease and Cirrhosis

Dr. Randeep Rana

MD, DM (AIIMS) • Consultant Gastroenterologist, Hepatologist & Pancreatologist

August 2026

Explore non-alcoholic fatty liver disease (NAFLD), cirrhosis complications like variceal bleeding, and breakthrough clinical trials on simvastatin and intravenous iron therapy.

The Progression of Non-Alcoholic Fatty Liver Disease

Non-Alcoholic Fatty Liver Disease (NAFLD) occurs when excess fat builds up in liver cells of people who drink little to no alcohol. It is closely linked to obesity, type 2 diabetes, metabolic syndrome, and high cholesterol. While often asymptomatic in early stages, NAFLD can progress to Non-Alcoholic Steatohepatitis (NASH), leading to inflammation, liver scarring, and eventually cirrhosis. Even non-overweight individuals can develop 'lean NAFLD,' requiring specialized clinical management.

Cirrhosis, Portal Hypertension & Variceal Bleeding

Cirrhosis is the late stage of scarring (fibrosis) of the liver. A major complication is portal hypertension — increased pressure in the portal vein carrying blood to the liver. This leads to varices (enlarged veins) in the esophagus or stomach, which are prone to sudden, life-threatening bleeding. Other complications include ascites (abdominal fluid) and hepatic encephalopathy.

Breakthrough Statin & Combination Therapies

Managing cirrhosis requires an evidence-based approach. Dr. Rana's clinical research explored the combination of simvastatin and rifaximin for decompensated cirrhosis patients, published in JAMA, aimed at reducing systemic inflammation and portal hypertension. Furthermore, his landmark trial in The American Journal of Gastroenterology demonstrated that adding simvastatin to standard care after variceal bleeding significantly improves long-term survival.

Optimizing Recovery After Variceal Bleeding

For patients recovering from variceal bleeding, managing iron deficiency anemia is critical. Dr. Rana's trial comparing intravenous ferric carboxymaltose versus oral iron therapy for iron deficiency anemia after variceal bleed in cirrhosis patients (published in AJG) provides crucial guidance for accelerating patient recovery.

Key Clinical Takeaways

Simvastatin addition to standard care improves long-term survival after variceal bleeding.

Lean NAFLD can occur without obesity and requires early FibroScan screening.

IV Ferric Carboxymaltose outperforms oral iron for post-bleeding anemia in cirrhosis.

Need Personal Medical Advice?

Schedule a personalized consultation with Dr. Randeep Rana at Max Smart Super Speciality Hospital, Saket.

Consult Dr. Randeep Rana